{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:15:30Z","timestamp":1790882130341,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008431","name":"Consejer\u00eda de Educaci\u00f3n, Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","award":["EDU\/1868\/2022"],"award-info":[{"award-number":["EDU\/1868\/2022"]}],"id":[{"id":"10.13039\/501100008431","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01432"],"award-info":[{"award-number":["PI24\/01432"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      <jats:italic>ZNF292<\/jats:italic>\n                      alterations are recurrently detected in patients with chronic lymphocytic leukemia (CLL), occurring in 3%-6% of patients as mutations and in 2% as 6q deletions. Although preliminary evidence suggested an independent prognostic role for\n                      <jats:italic>ZNF292<\/jats:italic>\n                      mutations, their specific clinical relevance in early-stage CLL and the underlying biological mechanisms remain poorly defined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      488 CLL patients were analyzed using targeted Next-Generation Sequencing (NGS) to characterize the landscape and clinical significance of\n                      <jats:italic>ZNF292<\/jats:italic>\n                      mutations. CRISPR\/Cas9-genome editing was employed to introduce the most prevalent\n                      <jats:italic>ZNF292<\/jats:italic>\n                      variants into CLL cellular models. Their biological and functional implications were evaluated by integrating RNA-sequencing data from these isogenic cellular models with transcriptomic data from primary patient samples, complemented by functional validation and drug response assays.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      <jats:italic>ZNF292<\/jats:italic>\n                      mutations were associated with shorter time to first treatment (TTFT; median 25 vs. 52 months,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.009) and inferior overall survival (OS, median 93 vs. 148 months,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004). Importantly, when restricting the analyses to early-stage cases,\n                      <jats:italic>ZNF292<\/jats:italic>\n                      alterations were independently associated with shorter TTFT and OS, identifying a high-risk subgroup. Mechanistically, transcriptomic analyses revealed that\n                      <jats:italic>ZNF292<\/jats:italic>\n                      mutations suppress global protein biosynthesis and modulate cell cycle progression in both primary CLL samples and CRISPR\/Cas9-edited cells. Furthermore,\n                      <jats:italic>ZNF292<\/jats:italic>\n                      deficiency impaired replication stress responses via defective CHK1 activation, resulting in DNA damage accumulation. Evaluating potential therapeutic vulnerabilities,\n                      <jats:italic>ZNF292<\/jats:italic>\n                      -mutated cells exhibited enhanced in vitro sensitivity to ibrutinib and venetoclax.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Our findings propose\n                      <jats:italic>ZNF292<\/jats:italic>\n                      alterations as an independent prognostic factor in early-stage CLL and unveil their role in disease progression.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40364-026-01005-y","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:36:58Z","timestamp":1790879818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ZNF292 mutations impair RNA and protein biosynthesis defining an adverse prognostic subset in early-stage chronic lymphocytic leukemia"],"prefix":"10.1186","volume":"14","author":[{"given":"Alberto","family":"Rodr\u00edguez-S\u00e1nchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Alonso-Gago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"P\u00e9rez-Carretero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis A.","family":"Corchete-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Miguel-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Santos-Minguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Villaverde-Ramiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Queiz\u00e1n-Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Araceli","family":"Rubio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"Benito-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico Lo","family":"Schiavo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Ghetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Simonetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana E.","family":"Rodr\u00edguez-Vicente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas M.","family":"Hern\u00e1ndez-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Quijada-\u00c1lamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"1005_CR1","doi-asserted-by":"crossref","unstructured":"Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, et al. Chronic lymphocytic leukaemia. Nat Rev Dis Primers. 2017;3:16096.","DOI":"10.1038\/nrdp.2016.96"},{"key":"1005_CR2","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1146\/annurev-pathmechdis-012419-032810","volume":"15","author":"F Nadeu","year":"2020","unstructured":"Nadeu F, Diaz-Navarro A, Delgado J, Puente XS, Campo E. Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia. Annu Rev Pathol Mech Dis. 2020;15:149\u201377.","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"7574","key":"1005_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/nature14666","volume":"526","author":"XS Puente","year":"2015","unstructured":"Puente XS, Be\u00e0 S, Vald\u00e9s-Mas R, Villamor N, Guti\u00e9rrez-Abril J, Mart\u00edn-Subero JI, et al. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015;526(7574):519\u201324.","journal-title":"Nature"},{"issue":"7574","key":"1005_CR4","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526(7574):525\u201330.","journal-title":"Nature"},{"issue":"11","key":"1005_CR5","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1038\/s41588-022-01140-w","volume":"54","author":"BA Knisbacher","year":"2022","unstructured":"Knisbacher BA, Lin Z, Hahn CK, Nadeu F, Duran-Ferrer M, Stevenson KE, et al. Molecular map of chronic lymphocytic leukemia and its impact on outcome. Nat Genet. 2022;54(11):1664\u201374.","journal-title":"Nat Genet"},{"issue":"29","key":"1005_CR6","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz T, Eichhorst B, Busch R, Denzel T, H\u00e4be S, Winkler D, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28(29):4473\u20139.","journal-title":"J Clin Oncol"},{"issue":"7354","key":"1005_CR7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature10113","volume":"475","author":"XS Puente","year":"2011","unstructured":"Puente XS, Pinyol M, Quesada V, Conde L, Ord\u00f3\u00f1ez GR, Villamor N, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101\u20135.","journal-title":"Nature"},{"issue":"7","key":"1005_CR8","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1084\/jem.20110921","volume":"208","author":"G Fabbri","year":"2011","unstructured":"Fabbri G, Rasi S, Rossi D, Trifonov V, Khiabanian H, Ma J, et al. Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389\u2013401.","journal-title":"J Exp Med"},{"issue":"5","key":"1005_CR9","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/leu.2012.357","volume":"27","author":"N Villamor","year":"2013","unstructured":"Villamor N, Conde L, Mart\u00ednez-Trillos A, Cazorla M, Navarro A, Be\u00e0 S, et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia. 2013;27(5):1100\u20136.","journal-title":"Leukemia"},{"issue":"1","key":"1005_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/leu.2013.263","volume":"28","author":"S Jeromin","year":"2014","unstructured":"Jeromin S, Weissmann S, Haferlach C, Dicker F, Bayer K, Grossmann V, et al. SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients. Leukemia. 2014;28(1):108\u201317.","journal-title":"Leukemia"},{"issue":"12","key":"1005_CR11","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.3324\/haematol.2018.187583","volume":"103","author":"E Campo","year":"2018","unstructured":"Campo E, Cymbalista F, Ghia P, J\u00e4ger U, Pospisilova S, Rosenquist R, et al. TP53 aberrations in chronic lymphocytic leukemia: An overview of the clinical implications of improved diagnostics. Haematologica. 2018;103(12):1956\u201368.","journal-title":"Haematologica"},{"issue":"2","key":"1005_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1038\/s41375-022-01802-y","volume":"37","author":"L Mansouri","year":"2023","unstructured":"Mansouri L, Thorvaldsdottir B, Sutton LA, Karakatsoulis G, Meggendorfer M, Parker H, et al. Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY. Leukemia. 2023;37(2):339\u201347.","journal-title":"Leukemia"},{"issue":"7762","key":"1005_CR13","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41586-019-1252-x","volume":"570","author":"M Gruber","year":"2019","unstructured":"Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, et al. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019;570(7762):474\u20139.","journal-title":"Nature"},{"issue":"2","key":"1005_CR14","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1080\/17474086.2020.1697225","volume":"13","author":"R Moia","year":"2020","unstructured":"Moia R, Patriarca A, Deambrogi C, Rasi S, Favini C, Kodipad AA, et al. An update on: molecular genetics of high-risk chronic lymphocytic leukemia. Expert Rev Hematol. 2020;13(2):109\u201316.","journal-title":"Expert Rev Hematol"},{"issue":"25","key":"1005_CR15","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360.","journal-title":"Blood"},{"issue":"3","key":"1005_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1002\/ajh.27546","volume":"100","author":"M Hallek","year":"2025","unstructured":"Hallek M, Chronic Lymphocytic L. 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy. Am J Hematol. 2025;100(3):450\u201380.","journal-title":"Am J Hematol"},{"key":"1005_CR17","doi-asserted-by":"crossref","unstructured":"Wu CJ, Caligaris-Cappio F, Chiorazzi N, Gribben JG, Hallek MJ, Wierda WG, et al. Unfinished business in chronic lymphocytic leukemia: translational and clinical priorities for a cure. Blood. 2026;148(2):175\u201386.","DOI":"10.1182\/blood.2025032393"},{"issue":"21","key":"1005_CR18","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1182\/blood.2019003453","volume":"135","author":"A Condoluci","year":"2020","unstructured":"Condoluci A, Di Bergamo LT, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135(21):1859\u201369.","journal-title":"Blood"},{"issue":"6","key":"1005_CR19","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.3324\/haematol.2019.228171","volume":"105","author":"JA Cohen","year":"2020","unstructured":"Cohen JA, Rossi FM, Zucchetto A, Bomben R, Terzi-Di-Bergamo L, Rabe KG, et al. A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. Haematologica. 2020;105(6):1613\u201320.","journal-title":"Haematologica"},{"issue":"4","key":"1005_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/joim.12455","volume":"279","author":"P Baliakas","year":"2016","unstructured":"Baliakas P, Mattsson M, Stamatopoulos K, Rosenquist R. Prognostic indices in chronic lymphocytic leukaemia: Where do we stand how do we proceed? J Intern Med. 2016;279(4):347\u201357.","journal-title":"J Intern Med"},{"issue":"11","key":"1005_CR21","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1038\/s41588-022-01211-y","volume":"54","author":"P Robbe","year":"2022","unstructured":"Robbe P, Ridout KE, Vavoulis DV, Dr\u00e9au H, Kinnersley B, Denny N, et al. Whole-genome sequencing of chronic lymphocytic leukemia identifies subgroups with distinct biological and clinical features. Nat Genet. 2022;54(11):1675\u201389.","journal-title":"Nat Genet"},{"issue":"1\u20132","key":"1005_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/S0303-7207(99)00200-2","volume":"159","author":"TC Vanderheyden","year":"2000","unstructured":"Vanderheyden TC, Wojtkiewicz PW, Voss TC, Mangin TM, Harrelson Z, Ahlers KM, et al. Mouse growth hormone transcription factor Zn-16: Unique bipartite structure containing tandemly repeated zinc finger domains not reported in rat Zn-15. Mol Cell Endocrinol. 2000;159(1\u20132):89\u201398.","journal-title":"Mol Cell Endocrinol"},{"issue":"1\u20132","key":"1005_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.gene.2005.10.010","volume":"368","author":"MP Flynn","year":"2006","unstructured":"Flynn MP, Hurley DL. Growth hormone transcription factor ZN-16 genomic coding regions are composed of a single exon and are evolutionarily conserved in mammals. Gene. 2006;368(1\u20132):78\u201383.","journal-title":"Gene"},{"issue":"3","key":"1005_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/leu.2017.291","volume":"32","author":"F Nadeu","year":"2018","unstructured":"Nadeu F, Clot G, Delgado J, Mart\u00edn-Garc\u00eda D, Baumann T, Salaverria I, et al. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia. Leukemia. 2018;32(3):645\u201353.","journal-title":"Leukemia"},{"issue":"26","key":"1005_CR25","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H D\u00f6hner","year":"2000","unstructured":"D\u00f6hner H, Stilgenbauer S, Benner A, Leupolt E, Kr\u00f6ber A, Bullinger L, et al. Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. N Engl J Med. 2000;343(26):1910\u20136.","journal-title":"N Engl J Med"},{"issue":"3","key":"1005_CR26","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/sj.leu.2403242","volume":"18","author":"A Cuneo","year":"2004","unstructured":"Cuneo A, Rigolin GM, Bigoni R, De Angeli A, Veronese A, Cavazzani F, et al. Chronic lymphocytic leukemia with 6q- shows distinct hematological features and intermediate prognosis. Leukemia. 2004;18(3):476\u201383.","journal-title":"Leukemia"},{"issue":"10","key":"1005_CR27","doi-asserted-by":"publisher","first-page":"E604","DOI":"10.1002\/ajh.24852","volume":"92","author":"M Jarosova","year":"2017","unstructured":"Jarosova M, Hruba M, Oltova A, Plevova K, Kruzova L, Kriegova E, et al. Chromosome 6q deletion correlates with poor prognosis and low relative expression of FOXO3 in chronic lymphocytic leukemia patients. Am J Hematol. 2017;92(10):E604\u20137.","journal-title":"Am J Hematol"},{"issue":"9","key":"1005_CR28","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/ajh.27421","volume":"99","author":"C P\u00e9rez Carretero","year":"2024","unstructured":"P\u00e9rez Carretero C, Gonz\u00e1lez T, Quijada \u00c1lamo M, Rigolin GM, Dubuc A, Villaverde Ramiro \u00c1, et al. Chronic lymphocytic leukemia patients with chromosome 6q deletion as the sole cytogenetic abnormality display a high frequency of RPS15 mutations and have a poor prognosis. Am J Hematol. 2024;99(9):1845\u20138.","journal-title":"Am J Hematol"},{"issue":"5897","key":"1005_CR29","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1126\/science.1164382","volume":"321","author":"DW Parsons","year":"2008","unstructured":"Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Sci (80-). 2008;321(5897):1807\u201312.","journal-title":"Sci (80-)"},{"issue":"7","key":"1005_CR30","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1111\/apm.12545","volume":"124","author":"JH Lee","year":"2016","unstructured":"Lee JH, Song SY, Kim MS, Yoo NJ, Lee SH. Frameshift mutations of a tumor suppressor gene ZNF292 in gastric and colorectal cancers with high microsatellite instability. Apmis. 2016;124(7):556\u201360.","journal-title":"Apmis"},{"issue":"65","key":"1005_CR31","doi-asserted-by":"publisher","first-page":"108923","DOI":"10.18632\/oncotarget.22408","volume":"8","author":"M Kluth","year":"2017","unstructured":"Kluth M, Jung S, Habib O, Eshagzaiy M, Heinl A, Amschler N, et al. Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. Oncotarget. 2017;8(65):108923\u201335.","journal-title":"Oncotarget"},{"issue":"3","key":"1005_CR32","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41436-019-0693-9","volume":"22","author":"GM Mirzaa","year":"2020","unstructured":"Mirzaa GM, Chong JX, Piton A, Popp B, Foss K, Guo H, et al. De novo and inherited variants in ZNF292 underlie a neurodevelopmental disorder with features of autism spectrum disorder. Genet Med. 2020;22(3):538\u201346.","journal-title":"Genet Med"},{"issue":"6","key":"1005_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.21147\/j.issn.1000-9604.2021.06.01","volume":"33","author":"W Gong","year":"2021","unstructured":"Gong W, Xu J, Wang G, Li D, Zhan Q. ZNF292 suppresses proliferation of ESCC cells through ZNF292\/SKP2\/P27 signaling axis. Chin J Cancer Res. 2021;33(6):637\u201348.","journal-title":"Chin J Cancer Res"},{"issue":"10","key":"1005_CR34","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1002\/ijc.33235","volume":"147","author":"C P\u00e9rez-Carretero","year":"2020","unstructured":"P\u00e9rez-Carretero C, Hern\u00e1ndez-S\u00e1nchez M, Gonz\u00e1lez T, Quijada-\u00c1lamo M, Mart\u00edn-Izquierdo M, Hern\u00e1ndez-S\u00e1nchez JM, et al. Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications. Int J Cancer. 2020;147(10):2780\u201392.","journal-title":"Int J Cancer"},{"issue":"7","key":"1005_CR35","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/ajh.26578","volume":"97","author":"C P\u00e9rez-Carretero","year":"2022","unstructured":"P\u00e9rez-Carretero C, Hern\u00e1ndez-S\u00e1nchez M, Gonz\u00e1lez T, Quijada-\u00c1lamo M, Mart\u00edn-Izquierdo M, Santos-M\u00ednguez S, et al. TRAF3 alterations are frequent in del-3\u2019IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features. Am J Hematol. 2022;97(7):903\u201314.","journal-title":"Am J Hematol"},{"issue":"6","key":"1005_CR36","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1038\/s41375-020-0714-3","volume":"34","author":"M Quijada-\u00c1lamo","year":"2020","unstructured":"Quijada-\u00c1lamo M, Hern\u00e1ndez-S\u00e1nchez M, Alonso-P\u00e9rez V, Rodr\u00edguez-Vicente AE, Garc\u00eda-Tu\u00f1\u00f3n I, Mart\u00edn-Izquierdo M, et al. CRISPR\/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition. Leukemia. 2020;34(6):1599\u2013612.","journal-title":"Leukemia"},{"issue":"17","key":"1005_CR37","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Zhou Y, Chen Y, Gu J, Fastp. An ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884\u201390.","journal-title":"Bioinformatics"},{"issue":"4","key":"1005_CR38","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nmeth.4197","volume":"14","author":"R Patro","year":"2017","unstructured":"Patro R, Duggal G, Love MI, Irizarry RA, Kingsford C. Salmon provides fast and bias-aware quantification of transcript expression. Nat Methods. 2017;14(4):417\u20139.","journal-title":"Nat Methods"},{"issue":"6","key":"1005_CR39","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/bioinformatics\/btz854","volume":"36","author":"C Prieto","year":"2020","unstructured":"Prieto C, Barrios D. RaNA-Seq: Interactive RNA-Seq analysis from FASTQ files to functional analysis. Bioinformatics. 2020;36(6):1955\u20136.","journal-title":"Bioinformatics"},{"issue":"1","key":"1005_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2009","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009;26(1):139\u201340.","journal-title":"Bioinformatics"},{"issue":"September","key":"1005_CR41","first-page":"1","volume":"4","author":"D Barrios","year":"2024","unstructured":"Barrios D, Prieto C, Rvisdiff. An R package for interactive visualization of differential expression. Front Bioinforma. 2024;4(September):1\u20135.","journal-title":"Front Bioinforma"},{"issue":"3","key":"1005_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21769\/BioProtoc.4933","volume":"14","author":"M Piecyk","year":"2024","unstructured":"Piecyk M, Fauvre J, Duret C, Chaveroux C, Ferraro-Peyret C. SUrface SEnsing of Translation (SUnSET), a Method Based on Western Blot Assessing Protein Synthesis Rates in vitro. Bio-protocol. 2024;14(3):1\u20138.","journal-title":"Bio-protocol"},{"issue":"1","key":"1005_CR43","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4161\/onci.1.1.18400","volume":"1","author":"A Ros\u00e9n","year":"2012","unstructured":"Ros\u00e9n A, Bergh AC, Gogol\u00e1k P, Evaldsson C, Myhrinder AL, Hellqvist E, et al. Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology. 2012;1(1):18\u201327.","journal-title":"Oncoimmunology"},{"issue":"6","key":"1005_CR44","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/ijc.2910410621","volume":"41","author":"N Lewin","year":"1988","unstructured":"Lewin N, \u00c5man P, Mellstedi H, Zech L, Klein G. Direct outgrowth of in vivo epstein-barr virus (EBV)\u2010infected chronic lymphocytic leukemia (CLL) cells into permanent lines. Int J Cancer. 1988;41(6):892\u20135.","journal-title":"Int J Cancer"},{"issue":"6404","key":"1005_CR45","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1126\/science.aap9346","volume":"361","author":"JC Saldivar","year":"2018","unstructured":"Saldivar JC, Hamperl S, Bocek MJ, Chung M, Bass TE, Cisneros-Soberanis F, et al. An intrinsic S\/G2 checkpoint enforced by ATR. Sci (80-). 2018;361(6404):806\u201310.","journal-title":"Sci (80-)"},{"issue":"1","key":"1005_CR46","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.bbcan.2013.12.002","volume":"1845","author":"F Yang","year":"2014","unstructured":"Yang F, Teves SS, Kemp CJ, Henikoff S, Doxorubicin. DNA torsion, and chromatin dynamics. Biochim Biophys Acta - Rev Cancer. 2014;1845(1):84\u20139.","journal-title":"Biochim Biophys Acta - Rev Cancer"},{"issue":"6","key":"1005_CR47","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1158\/1078-0432.CCR-18-4158","volume":"26","author":"C Brieghel","year":"2020","unstructured":"Brieghel C, da Cunha-Bang C, Yde CW, Schmidt AY, Kinalis S, Nadeu F, et al. The number of signaling pathways altered by driver mutations in chronic lymphocytic leukemia impacts disease outcome. Clin Cancer Res. 2020;26(6):1507\u201315.","journal-title":"Clin Cancer Res"},{"key":"1005_CR48","doi-asserted-by":"crossref","unstructured":"Martino EA, Caserta S, Vigna E, Cutrona G, Bruzzese A, Mendicino F, et al. To treat or not to treat: navigating early-stage CLL in the era of targeted therapy. Eur J Haematol. 2026;117(4):750\u201366.","DOI":"10.1111\/ejh.70219"},{"issue":"22","key":"1005_CR49","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2017-09-804401","volume":"132","author":"G Bretones","year":"2018","unstructured":"Bretones G, \u00c1lvarez MG, Arango JR, Rodr\u00edguez D, Nadeu F, Prado MA, et al. Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia. Blood. 2018;132(22):2375\u201388.","journal-title":"Blood"},{"issue":"13","key":"1005_CR50","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1182\/bloodadvances.2020001717","volume":"5","author":"S Ntoufa","year":"2021","unstructured":"Ntoufa S, Gerousi M, Laidou S, Psomopoulos F, Tsiolas G, Moysiadis T, et al. RPS15 mutations rewire RNA translation in chronic lymphocytic leukemia. Blood Adv. 2021;5(13):2788\u201392.","journal-title":"Blood Adv"},{"issue":"12","key":"1005_CR51","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.1158\/2767-9764.CRC-23-0306","volume":"3","author":"S O\u2019Brien","year":"2023","unstructured":"O\u2019Brien S, Ubhi T, Wolf L, Gandhi K, Lin S, Chaudary N, et al. FBXW7-loss Sensitizes Cells to ATR Inhibition Through Induced Mitotic Catastrophe. Cancer Res Commun. 2023;3(12):2596\u2013607.","journal-title":"Cancer Res Commun"},{"key":"1005_CR52","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1146\/annurev-genet-080320-031523","volume":"57","author":"L Goehring","year":"2023","unstructured":"Goehring L, Huang TT, Smith DJ. Transcription-Replication Conflicts as a Source of Genome Instability. Annu Rev Genet. 2023;57:157\u201379.","journal-title":"Annu Rev Genet"},{"issue":"3","key":"1005_CR53","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/bjh.18609","volume":"201","author":"S Carrillo-Tornel","year":"2023","unstructured":"Carrillo-Tornel S, Chen-Liang TH, Zurdo M, Puiggros A, G\u00f3mez-Llon\u00edn A, Garc\u00eda-Malo MD, et al. NOTCH1 mutation in chronic lymphocytic leukaemia is associated with an enhanced cell cycle G1\/S transition and specific cyclin overexpression: Preclinical ground for targeted inhibition. Br J Haematol. 2023;201(3):470\u20139.","journal-title":"Br J Haematol"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01005-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-026-01005-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-026-01005-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T18:37:00Z","timestamp":1790879820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40364-026-01005-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1186\/s40364-026-01005-y","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"assertion":[{"value":"8 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the\n                      Comit\u00e9 \u00c9tico de Investigaci\u00f3n Cl\u00ednica\n                      of the\n                      Hospital Universitario de Salamanca\n                      . Written informed consent was obtained from all participants prior to inclusion, and the study was conducted in accordance with the principles of the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"130"}}